![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab/content/container_684832781/container_301131002_/image.img.png/1619038055165/icon-a1c-circle.png)
Once-weekly Ozempic® mechanism of action
GLP-1 RA stimulates the body’s own insulin secretion
GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. Ozempic® acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.1
REALIZE THE POTENTIAL WITH OZEMPIC®
Blue-label pen only delivers the maximum maintenance dose of 1 mg1
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_1906997201_copy/content/container/container_copy/image.img.png/1618060905357/ozempic-blue-pen.png)
Contains 4 mg of Ozempic® in a 3 mL pen
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_1906997201_copy/content/container/image.img.png/1618060897062/ozempic-shadow-bottom.png)
Blue-label pen only delivers the maximum maintenance dose of 1 mg1
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_1906997201_copy/content/container_copy/container_copy/image.img.png/1618060905357/ozempic-blue-pen.png)
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_1906997201_copy/content/container_copy/image.img.png/1618060897062/ozempic-shadow-bottom.png)
Blue-label pen only delivers the maximum maintenance dose of 1 mg1
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_1906997201_copy_1639138988/content/container/container_copy/image.img.png/1618060905357/ozempic-blue-pen.png)
Contains 4 mg of Ozempic® in a 3 mL pen
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_1906997201_copy_1639138988/content/container/image.img.png/1618060897062/ozempic-shadow-bottom.png)
Blue-label pen only delivers the maximum maintenance dose of 1 mg1
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_1906997201_copy_1639138988/content/container_copy_copy/container_copy/image.img.png/1618060905357/ozempic-blue-pen.png)
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_1906997201_copy_1639138988/content/container_copy_copy/image.img.png/1618060897062/ozempic-shadow-bottom.png)
Blue-label pen only delivers the maximum maintenance dose of 1 mg1
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_1906997201_copy_381805559/content/container/container_copy/image.img.png/1618060905357/ozempic-blue-pen.png)
Contains 4 mg of Ozempic® in a 3 mL pen
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_1906997201_copy_381805559/content/container/image.img.png/1618060897062/ozempic-shadow-bottom.png)
Blue-label pen only delivers the maximum maintenance dose of 1 mg1
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_1906997201_copy_381805559/content/container_copy/container_copy/image.img.png/1618060905357/ozempic-blue-pen.png)
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_1906997201_copy_381805559/content/container_copy/image.img.png/1618060897062/ozempic-shadow-bottom.png)
Resources for starting patients
Whether you’re starting your patients on Ozempic® in person or via telehealth, use these quick links to find all the resources you need.
Blue-label pen only delivers the maximum maintenance dose of 1 mg1
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_1906997201_copy_967222835/content/container/container_copy/image.img.png/1618060905357/ozempic-blue-pen.png)
Contains 4 mg of Ozempic® in a 3 mL pen
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_1906997201_copy_967222835/content/container/image.img.png/1618060897062/ozempic-shadow-bottom.png)
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_1906997201_copy_967222835/content/container_copy/container/image.img.png/1619043042557/icon-resources-rx.png)
Dosing information
Learn about dosing Ozempic® and ways to share this information with your patients.
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_1906997201_copy_967222835/content/container_copy/image.img.png/1618060897062/ozempic-shadow-bottom.png)
Resources for starting patients
Whether you’re starting your patients on Ozempic® in person or via telehealth, use these quick links to find all the resources you need.
Outer shadow
Inner shadow
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_2103879816/content/image_copy.img.gif/1624284165557/chart-vsjardiance-a1c-reduction-lg.gif)
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_309070522/content/container_1490087722/container/image.img.png/1619800630822/hero-maverick-lg.png)
Pen shown delivers doses of
0.25 mg or 0.5 mg.
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_309070522/content/container_1490087722/container_1257649646/container_450255651_/image_copy.img.png/1619800127892/icon-a1c-circle.png)
Unmatched glycemic control
Superior results vs Trulicity® (in SUSTAIN 7)b and as an add-on to basal insulin and statistically significant results vs study-titrated Lantus®.1,2
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_309070522/content/container_1490087722/container_1257649646/container_450255651/image_copy_1989091612.img.png/1622754678638/icon-weight-circle.png)
Significant weight reduction1,2,c
Ozempic® is not indicated for weight loss.
![](/diabetes/products/treatments/ozempic/explorations/_jcr_content/root/slab_309070522/content/container_1490087722/container_1257649646/container_450255651__514127214/image_copy_913598677.img.png/1621617628759/icon-cv-circle.png)
SIGNIFICANT REDUCTION IN RISK OF MACE1,a,d
Evaluated in a 2-year CVOT vs placebo in adults with type 2 diabetes and established CVD.
aMajor adverse CV events (MACE)=CV death, nonfatal MI, or nonfatal stroke.
bSUSTAIN 7 included 0.5 mg and 1.0 mg doses for Ozempic® and 0.75 mg and 1.5 mg doses for Trulicity®.
cWeight change was a secondary endpoint in clinical trials.
dResults apply to Ozempic® plus standard of care vs standard of care alone in SUSTAIN 6 trial for patients with T2D and established CVD.
T2D=type 2 diabetes; CVD=cardiovascular disease; CVOT=cardiovascular outcomes trial; CV=cardiovascular; GLP-1 RA=glucagon-like peptide-1 receptor agonist; MI=myocardial infarction.